Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.85 |
| ▸ | ALPI | P09923 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | XIAP | P98170 | 1/20 | 0.85 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL27873303 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL246542 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL11240666 | 0.98 | SLC7A5 (0.81) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL8610376 | 0.93 | SLC7A5 (0.79) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL8610372 | 0.93 | SLC7A5 (0.79) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL8118 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL16398196 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL385804 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL8119 | 0.92 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034169-A1 | STABILISED SILICIC ACID SOLUTIONS | BARLAA B.V. (NL) | 2026-02-05 | — | — | US | disclosed |
| EP-4565530-A1 | STABILISED SILICIC ACID SOLUTIONS | Barlaa B.V. (NL) | 2025-06-11 | — | — | EP | disclosed |
| CN-119894823-A | Stable silicic acid solutions | 巴尔拉有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113651959-B | Nanometer medicine carrying system based on amino acid-hydroxy acid copolymer and preparation method and application thereof | 中山大学 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024028039-A1 | STABILISED SILICIC ACID SOLUTIONS | BARLAA B.V. (NL) | 2024-02-08 | — | — | WO | disclosed |
| CN-112603908-B | Nano drug-loading system based on amino acid polymer and preparation method and application thereof | 中山大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-113651959-A | Nano drug loading system based on amino acid-hydroxy acid copolymer and preparation method and application thereof | 中山大学 | 2021-11-16 | — | — | CN | disclosed |
| CN-112603908-A | Nano drug-loading system based on amino acid polymer and preparation method and application thereof | 中山大学 | 2021-04-06 | — | — | CN | disclosed |
| CN-102698808-B | The purposes of a kind of composite catalyst and clean catalytic oxidization cyclohexene synthesizing adipic acid thereof | BEIJING XUYANG CHEMICAL TECHNOLOGY RESEARCH INSTITUTE CO., LTD. (CN) | 2015-07-29 | — | — | CN | disclosed |
| EP-2330124-B1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2002094873-A2 | PREPARATION OF CHOLECYSTOKININ AGONISTS AND ANTAGONISTS, AND THEIR THERAPEUTIC AND DIAGNOSTIC USE | BRACCO IMAGING S.P.A. (IT) | 2002-11-28 | — | — | WO | disclosed |
| US-20020102256-A1 | Peptide and polypeptide inhibitors of complement C1s | ZYMOGENETICS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001098365-A2 | PEPTIDE AND POLYPEPTIDE INHIBITORS OF COMPLEMENT C1S | ZYMOGENETICS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| US-5723576-A | POLYPEPTIDES FOR ENZYME INHIBITORS AND HIRUNDIN | DEVELOPMENT BIOTECHNOLOGICAL PROCESSES S.N.C. (IT) | 1998-03-03 | — | — | US | disclosed |
| EP-0376230-B1 | Preparation and isolation of mineral acid salt of an amino methyl ester | MITSUI TOATSU CHEMICALS (JP) | 1994-11-23 | — | — | EP | disclosed |
| US-5113009-A | PREPARATION AND ISOLATION OF MINERAL ACID SALT OF AN AMINO ACID METHYL ESTER | MITSUI TOATSU CHEMICALS, INCORPORATED | 1992-05-12 | — | — | US | disclosed |
| EP-0376230-A2 | Preparation and isolation of mineral acid salt of an amino methyl ester | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0057092-B1 | PROCESS FOR RACEMIZING AN OPTICALLY ACTIVE ALPHA-AMINO ACID OR A SALT THEREOF | Tanabe Seiyaku Co., Ltd. (JP) | 1985-05-02 | — | — | EP | disclosed |
| US-4401820-A | IN THE PRESENCE OF AN ACYCLIC ACID AND AN ALDEHYDE; STABILITY | TANABE SEIYAKU CO., LTD. (JP) | 1983-08-30 | — | — | US | disclosed |
| EP-0057092-A1 | Process for racemizing an optically active alpha-amino acid or a salt thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1982-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034169-A1 | STABILISED SILICIC ACID SOLUTIONS | HAO2, SMS, SSTR2 | SLC7A5 14/4885PTGS1 1633/4885ALPI 2144/4885 |
| US-20020102256-A1 | Peptide and polypeptide inhibitors of complement C1s | C1S, C1QBP, C1R | SLC7A5 3648/4885PTGS1 2655/4885ALPI 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.